普瑞巴林联合鞘内输注舒芬太尼治疗骨转移癌 爆发痛的临床研究

目的：探讨普瑞巴林联合鞘内输注舒芬太尼治疗骨转移癌爆发痛的临床疗效。方法：将60例骨转移癌爆发
痛患者随机分成3组：A组(普瑞巴林+鞘内输注舒芬太尼组，n=20)，B组(安慰剂+鞘内输注舒芬太尼组，n=20)和C组
(口服硫酸吗啡控释片组，n=20)。采用疼痛视觉模拟评分(visual analogue scale，VAS)评估3组患者治疗后基础痛及爆发
痛的强度，并观察爆发痛的发作频率、总体满意度(general satisfaction，GSS)及不良反应。结果：与B组和C组比较，A
组患者的基础痛及爆发痛VAS评分和发作频率显著降低(P<0.05)，患者的GSS最高 (P<0.05)，恶心呕吐、嗜睡及便秘等
不良反应少。结论：普瑞巴林联合鞘内输注舒芬太尼能有效减轻骨转移癌基础痛和爆发痛。

Pregabalin combined with intrathecal sufentanil infusion for breakthrough pain in patients with bone metastases

Objective: To evaluate the analgesic effect of pregabalin combined with intrathecal sufentanil
infusion for the treatment of breakthrough pain in patients with bone metastases.
Methods: A total of 60 breakthrough pain patients with bone metastases were randomly divided to
3 groups: group A (pregabalin combined with intrathecal sufentanil infusion group, n=20), group B
(placebo combined with intrathecal sufentanil infusion group, n=20) and group C (oral morphine
sulfate controlled-release tablet group, n=20). The differences in visual analogue scale (VAS) between background pain and breakthrough pain, the seizure frequency of breakthrough pain,
general satisfaction and side effects of the 3 groups were observed.
Results: The seizure frequency and VAS of breakthrough pain in group A decreased significantly
after the treatment (P<0.05) and the general satisfaction was the best among the the 3 groups
(P<0.05), with less nausea and vomiting, constipation, drowsiness and fewer other side effects.
Conclusion: Pregabalin combined with intrathecal sufentanil infusion can effectively relieve
breakthrough pain in patients with bone metastases.